CVRxCVRX
CVRX
About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Employees: 206
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
29% more call options, than puts
Call options by funds: $736K | Put options by funds: $569K
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
1% more funds holding
Funds holding: 93 [Q4 2024] → 94 (+1) [Q1 2025]
2% more capital invested
Capital invested by funds: $192M [Q4 2024] → $195M (+$3.19M) [Q1 2025]
1.14% less ownership
Funds ownership: 62.47% [Q4 2024] → 61.33% (-1.14%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
19%
upside
Avg. target
$12.75
118%
upside
High target
$18
207%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
Piper Sandler Matt O'Brien | 105%upside $12 | Overweight Maintained | 9 May 2025 |
JP Morgan Robbie Marcus | 19%upside $7 | Underweight Downgraded | 9 May 2025 |
Lake Street Frank Takkinen | 139%upside $14 | Buy Maintained | 8 Apr 2025 |
Canaccord Genuity William Plovanic | 207%upside $18 | Buy Maintained | 8 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
Neutral
Seeking Alpha
1 month ago
CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago.
Negative
Zacks Investment Research
1 month ago
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
Positive
Seeking Alpha
2 months ago
CVRx Inc: Overreaction Creates Buying Opportunity
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
Negative
Benzinga
2 months ago
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.
Neutral
GlobeNewsWire
2 months ago
CVRx Reports Preliminary First Quarter 2025 Financial Results
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024
Neutral
GlobeNewsWire
4 months ago
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
Neutral
Zacks Investment Research
4 months ago
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Charts implemented using Lightweight Charts™